Journal
VIROLOGY
Volume 547, Issue -, Pages 7-11Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.virol.2020.05.002
Keywords
SARS-COV-2; COVID-19; Auranofin; Antiviral; Anti-inflammatory
Categories
Funding
- National Institute of Neurological Disorders and Stroke [R21NS099838]
- Office of the Director, National Institutes of Health [R21OD024896]
Ask authors/readers for more resources
SARS-COV-2 has recently emerged as a new public health threat Herein, we report that the FDA-approved drug, auranofin, inhibits SARS-COV-2 replication in human cells at low micro molar concentration. Treatment of cells with auranofin resulted in a 95% reduction in the viral RNA at 48 h after infection. Auranofin treatment dramatically reduced the expression of SARS-COV-2-induced cytokines in human cells. These data indicate that auranofin could be a useful drug to limit SARS-00V-2 infection and associated lung injury due to its antiviral, anti-inflammatory and anti-reactive oxygen species (ROS) properties. Further animal studies are warranted to evaluate the safety and efficacy of auranofin for the management of SARS-COV-2 associated disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available